Riskpilot← Back to searchSign inGet full accessMedlack AB
ABActiveOrg 5566181193Östra Ågatan 39Research and experimental development on natural sciences and engineering · NACE 7210Est. 20010 employees
Revenue 2025
SEK 131K
-51% vs 2024
EBITDA margin
-47.3%
-168% vs 2024
Equity ratio
93.5%
Financial strength
Net profit 2025
SEK 25K
-63% vs 2024
| Revenue | SEK 131K | -51% |
| EBITDA | SEK -62K | -168% |
| Net profit | SEK 25K | -63% |
| Total assets | SEK 153K | -25% |
| Equity | SEK 143K | +21% |
| Employees | 0 | — |
Legal name
Medlack AB
Org number
5566181193
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
7 november 2001
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva utveckling, forskning, utbildning och konsultverksamhet inom det medicinska området, prövning och försäljning inom läkemedelsområdet, konferensverksamhet och uthyrning av fastigheter samt handel med värdepapper samt därmed förenlig verksamhet.
Address
Östra Ågatan 39
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 93 | 479 | 454 | 332 | 375 | 346 | 268 | 131 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −28 | 8 | −5 | 320 | 226 | 93 | 15 | 1 | 91 | −62 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −28 | 8 | −5 | 320 | 226 | 93 | 15 | 1 | 91 | −62 |
| Net financials | −37 | −9 | −6 | −424 | −300 | 98 | −392 | −83 | −1 | −224 |
| Profit before tax | −65 | −1 | −10 | 108 | 76 | 191 | −181 | −42 | 90 | 25 |
| Tax | 13 | −2 | −0 | −74 | −55 | −25 | −20 | −9 | −23 | −0 |
| Net profit | −52 | −3 | −10 | 34 | 21 | 166 | −201 | −51 | 67 | 25 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 385 | 333 | 309 | 417 | 431 | 449 | 199 | 63 | 203 | 153 |
| Equity | 58 | 55 | 101 | 135 | 126 | 272 | 58 | 51 | 118 | 143 |
| Long-term debt | 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 301 | 278 | 208 | 283 | 305 | 177 | 141 | 12 | 85 | 10 |
| Total debt | 327 | 278 | 208 | 283 | 305 | 177 | 141 | 12 | 85 | 10 |
EBITDA margin
-47.3%
This company
15.8%
Market median
-399% vs market
20162025
Equity ratio
93.5%
This company
38.2%
Market median
+145% vs market
20162025
Return on equity
17.5%
This company
18.4%
Market median
+5% vs market
20162025
Net profit margin
19.1%
This company
8.1%
Market median
+136% vs market
20162025
Asset turnover
0.86×
This company
1.12×
Market median
+23% vs market
20162025
Debt / equity
0.07×
This company
0.62×
Market median
+89% vs market
20162025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-05-01 – 2020-04-30
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-05-01 – 2019-04-30
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-05-01 – 2018-04-30
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-05-01 – 2017-04-30
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-05-01 – 2016-04-30
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Medlack AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Göran Läckgren | Board of Directors | 0 companies |
| G Christina E Läckgren Hägnefors | Deputy Board Member | 0 companies |